Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
Low enrollment indicates that beneficiaries have trouble figuring out whether reductions in cost sharing would offset a much higher premium.
Report by the Institute for Clinical and Economic Review will seek to inform the public policy debate on price increases for prescription drugs.
HHS secretary notes Medicare Part B International Pricing Index could ‘harness’ biosimilar price competition seen abroad for US market, where follow-ons have not been able to significantly impact pricing.
Manufacturers will avoid direct interrogation in first round, but Oversight Committee also seeking information from sponsors on reasons behind price increases. In US Senate, Susan Collins writes to HHS Secretary Alex Azar urging the department to move ahead with rebate reform.
Purchasing contract for state Medicaid and Corrections programs would last up to five years and aim to treat more than 10,000 patients in first year.
In format that industry hopes becomes alternative to government-mandated inclusion of list price on TV, Lilly webpage notes cost sharing associated with 35% of Medicare Part D claims is $180 per month, and is lower for the remaining 65%. Patients who haven’t met their deductible will see “higher prices.”